CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

OXNARD, Calif., May 22, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC).